Literature DB >> 28194857

Hepatitis E risks: pigs or blood-that is the question.

Richard S Tedder1,2,3, Samreen Ijaz1, Alan Kitchen2, Ines Ushiro-Lumb2, Kate I Tettmar2, Patricia Hewitt2, Nick Andrews4.   

Abstract

BACKGROUND: Infection with hepatitis E virus (HEV) Genotype 3 is recognized as a food-borne zoonosis in developed countries where it usually causes a mild self-limited acute hepatitis. It may cause a persistent infection in the immunosuppressed human that can progress to cirrhosis. To protect the patient from transfusion-acquired HEV infection, steps have been taken in the United Kingdom to provide for at-risk patients only components from donors screened for HEV viremia. This strategy does not protect from dietary exposure and calls into question estimation of relative risk between blood transfusion and diet. STUDY DESIGN AND METHODS: Using data on HEV viremia, component exposure, residual plasma volume, and resulting transmission, the dose of virus administered and subsequent transmission rates were determined and used to populate a model that can infer the relationship between blood and dietary exposure.
RESULTS: The annual attack rate of a population, defined as seroconversion, provides an estimate of the risk of receiving a component containing HEV from a viremic donor. The lowest viral dose that resulted in infection was 2 × 104 IUs and 55% of components containing this dose transmitted infection. The transfusion risk of infection only exceeds the annual dietary risk when more than 13 individual donor components are transfused.
CONCLUSION: For many solid organ transplant patients dietary exposure far exceeds the risk of transfusion from unscreened donors. It is only in the immunosuppressed patient requiring extensive blood component support that transfusion risk dominates. This understanding should inform policy decisions on HEV RNA screening of blood donations.
© 2017 AABB.

Entities:  

Mesh:

Year:  2017        PMID: 28194857     DOI: 10.1111/trf.13976

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  18 in total

1.  Toward Systematic Screening for Persistent Hepatitis E Virus Infections in Transplant Patients.

Authors:  Michael J Ankcorn; Samreen Ijaz; John Poh; Ahmed M Elsharkawy; Erasmus Smit; Robert Cramb; Swathi Ravi; Kate Martin; Richard Tedder; James Neuberger
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 2.  Hiding in Plain Sight? It's Time to Investigate Other Possible Transmission Routes for Hepatitis E Virus (HEV) in Developed Countries.

Authors:  Nicola J King; Joanne Hewitt; Anne-Marie Perchec-Merien
Journal:  Food Environ Virol       Date:  2018-04-05       Impact factor: 2.778

3.  Early hepatitis E infection in an unrelated hematopoietic progenitor stem cell donor.

Authors:  D O'Donghaile; N O'Flaherty; S Field
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

4.  Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.

Authors:  Carme Ballester-Servera; Teresa Jimenez-Marco; Daniel Morell-Garcia; Miguel Quetglas-Oliver; Antonia M Bautista-Gili; Enrique Girona-Llobera
Journal:  Blood Transfus       Date:  2020-05-15       Impact factor: 3.443

Review 5.  Blood Donor Screening for Hepatitis E Virus in the European Union.

Authors:  Fiona Boland; Auxiliadora Martinez; Louise Pomeroy; Niamh O'Flaherty
Journal:  Transfus Med Hemother       Date:  2019-03-14       Impact factor: 3.747

6.  Probable transmission of hepatitis E virus (HEV) via transfusion in the United States.

Authors:  John R Ticehurst; Nora Pisanic; Michael S Forman; Carly Ordak; Christopher D Heaney; Edgar Ong; Jeffrey M Linnen; Paul M Ness; Nan Guo; Hua Shan; Kenrad E Nelson
Journal:  Transfusion       Date:  2019-01-31       Impact factor: 3.157

7.  Hepatitis E and blood donation safety in selected European countries: a shift to screening?

Authors:  Dragoslav Domanović; Richard Tedder; Johannes Blümel; Hans Zaaijer; Pierre Gallian; Christoph Niederhauser; Silvia Sauleda Oliveras; Joan O'Riordan; Fiona Boland; Lene Harritshøj; Maria São José Nascimento; Anna Rita Ciccaglione; Constatina Politis; Cornelia Adlhoch; Benoit Flan; Wahiba Oualikene-Gonin; Guy Rautmann; Paul Strengers; Patricia Hewitt
Journal:  Euro Surveill       Date:  2017-04-20

8.  Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose.

Authors:  Jens Dreier; Cornelius Knabbe; Tanja Vollmer
Journal:  Front Med (Lausanne)       Date:  2018-02-01

Review 9.  Convalescent Plasma Therapy for COVID-19: State of the Art.

Authors:  Daniele Focosi; Arthur O Anderson; Julian W Tang; Marco Tuccori
Journal:  Clin Microbiol Rev       Date:  2020-08-12       Impact factor: 26.132

10.  Hepatitis E virus prevalence among blood donors in Dali, China.

Authors:  Ping Fu; Baochai Lin; Bingting Wu; Ling Ke; Tianfu Yang; Yue'e Du; Lishan Cheng; Zhou Li; Tiancheng Li; Yu Liu
Journal:  Virol J       Date:  2021-07-07       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.